Experimmune, a center dedicated to research in the field of immunotherapy and product development, established by the Texas Tech University Health Sciences Center (TTUHSC) and the Development Corporation of Abilene, announced the creation of a Tumor Immunology and Vaccine Core (TIVC), in order to promote research and development (R&D) activities related to unmet need for drug discovery, as well as translational development of immunotherapies for oncology.
Operated by Experimmune and located at AbLabs in Abilene, the TIVC is planned to be a state-of-the-art multidisciplinary facility, where researchers will be able to produce discovery, pre-clinical development and testing services for tumor immunotherapeutics, all dedicated to accelerating the translational research process.
Academic principal investigators along with industry and physicians working on cancer immunotherapy, will be able to use the facility’s comprehensive collection of technical expertise, which is comprised of bioassay and companion diagnostic development, high-throughput/high-content/combinatorial screens for biomolecules, experimental design planning, project management and regulatory consultation.
The TIVC provides a comprehensive collection of technical expertise that includes bioassay and companion diagnostic development, high-throughput/high-content/combinatorial screens for biomolecules, experimental design planning, project management and regulatory consultation. The focus of the TIVC is relevant to academic principal investigators, industry and physician teams involved in cancer immunotherapy.
The Experimmune center itself is a result of a partnership with the purpose of creating a facility dedicated to research on the field of immunotherapy, and product development, as well as fulfill the need to conduct the research findings on immunology into immunotherapies for several diseases, and contract R&D services to academic investigators, life science investors and biotechnology companies.
The center’s work is directed by the Good Laboratory Practice (GLP) guidelines, and provides support to cancer scientists who are conducting breakthrough research, especially regarding the submission of publications and the acquisition of grants, since its inauguration last year. Experimmune is also operating in collaboration with biotechnology companies in the pre-clinical development of lead therapeutic antibodies for cancer treatment.
